Item 8.01 Other Events.

On November 23, 2020, Generex Biotechnology Corporation and its majority owned subsidiary NuGenerex Immuno-Oncology, Inc., (collectively "Generex") signed a non-binding memorandum of understanding (MOU) with Bintai Healthcare SDN. BHD., a subsidiary of Bintai Kinden Corporation Berhad, a public listed company in Malaysia listed on Bursa Malaysia ("Bintai") to exercise Bintai's right of first refusal to commercialize the Generex proprietary Ii-Key-SARS-CoV-2 coronavirus vaccine ("Vaccine") within Australia and New Zealand as set forth in the signed October 5, 2020, Distribution and Licensing Agreement between Generex and Bintai.

The parties executed the MOU to further negotiate the terms and conditions wherein Generex will license Bintai to have the sole rights to market, distribute, supply and sell the Vaccine to Australia and New Zealand. The MOU is not intended to be legally binding and no legal obligations or legal rights shall arise between the parties from the provisions of the MOU.

Generex filed a FORM 8K for the signed October 5, 2020, Distribution and Licensing Agreement between Generex and Bintai on October 9, 2020.





Ii-Key Platform Overview

Ii-Key is a platform technology enabled by the amino acid key sequence "LRMK" that is shared across the platform. The LRMK key sequence works by its ability to deliver any desired peptide epitope of interest directly to the MHC Class 2 complex on the surface of antigen presenting cells. Once a suitable target epitope is identified, an Ii-Key vaccine candidate is created by means of synthetic peptide synthesis, which produces a single linear amino acid chain that includes the Ii-Key sequence, a short inert linker sequence, and the target epitope of interest. In this way, the target epitope is delivered by the Ii-Key sequence directly to antigen presenting cells, resulting in an immune system stimulation.

A copy of the MOU signed November 23, 2020, is filed as Exhibit 99.1 to this report.

On November 23, 2020, Generex issued a press release announcing the MOU with Bintai as described above, a copy of which is filed as Exhibit 99.2 to this report.





About Bintai Kinden

With over 40 years of specialist engineering and construction experience, Bintai's unique combination of extensive regional experience and local knowledge has made them the region's international contractor of choice. Headquartered in Malaysia, Bintai Kinden has expanded operations regionally throughout South-East Asia, China and the Arabian Gulf region.

As multi-disciplined, building and industrial service engineers and specialists, Bintai works in all the major market sectors, from commercial buildings to industrial complexes, designing, installing and commissioning systems that include the full range of engineering services.

Looking beyond today's frontiers, Bintai Kinden is confident that it has the resources, technical expertise and progressive mindset to consolidate its position globally. The integration of research, management, marketing and sales that transcends organizational borders enables Bintai Kinden to capitalize on synergistic potential and benefits of scale.





Forward-Looking Statements

Statements in this report may contain certain forward-looking statements. All statements included concerning activities, events or developments that the Generex expects, believes or anticipates will or may occur in the future are forward-looking statements. Actual results could differ materially from the results discussed in the forward-looking statements. Forward-looking statements are based on current expectations and projections about future events and involve known and unknown risks, uncertainties and other factors that may cause actual results and performance to be materially different from any future results or performance expressed or implied by forward-looking statements. Known risks and uncertainties also include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act. Additional information on these and other risks, uncertainties and factors is included in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8- K and other documents filed with the SEC.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No. Description

99.1        MOU signed November 23, 2020
99.2        Press Release dated November 23, 2020


  2

© Edgar Online, source Glimpses